Systemic treatment of colorectal cancer.

  title={Systemic treatment of colorectal cancer.},
  author={Brian Wolpin and Robert J. Mayer},
  volume={134 5},
Colorectal cancer is the fourth most common noncutaneous malignancy in the United States and the second most frequent cause of cancer-related death. Over the past 12 years, significant progress has been made in the systemic treatment of this malignant condition. Six new chemotherapeutic agents have been introduced, increasing median overall survival for patients with metastatic colorectal cancer from less than 9 months with no treatment to approximately 24 months. For patients with stage III… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 181 extracted citations


Publications referenced by this paper.
Showing 1-10 of 133 references

EGFR , HER 2 , Kras as predictive factors for cetuximab sensitivity in colorectal cancer ( abstr )

  • G Finocchiaro, F Cappuzzo, PA Janne
  • J Clin Oncol
  • 2008

Bevacizumab ( Bev ) in combination with XELOX or FOLFOX 4 : updated efficacy results from XELOX1 / NO 16966 , a randomized phase III trial in first - line metastatic colorectal cancer ( abstr )

  • L Saltz, S Clarke, E Diaz-Rubio
  • J Clin Oncol
  • 2007

Similar Papers

Loading similar papers…